PharmaLundensis AB (PHAL)

Overview

PharmaLundensis AB is a pharmaceutical company based in Lund, Sweden, established in 2006. The company is dedicated to the development of innovative treatments for respiratory diseases and implementing solutions to reduce environmental impact from pharmaceutical residues. Its focus areas include chronic obstructive pulmonary disease (COPD), chronic bronchitis, influenza-induced lung failure, and the reduction of pharmaceutical drugs and multi-resistant bacteria release into hospital wastewater.

Products and Services

• Iodocarb

  A therapeutic product developed by PharmaLundensis AB, aimed at treating chronic obstructive pulmonary disease (COPD). This treatment represents the company's dedication to addressing severe respiratory conditions that affect millions of people worldwide.

• Chronic Bronchitis and Influenza-induced Lung Failure Treatments

  These treatments are part of PharmaLundensis AB's portfolio for addressing specific respiratory ailments beyond COPD. By focusing on chronic bronchitis and the severe complications arising from influenza, the company aims to provide solutions that can alleviate symptoms and potentially save lives.

• EcoFilter

  An innovative system developed to tackle the environmental challenges posed by the release of pharmaceutical drugs and multi-resistant bacteria in hospital wastewater. EcoFilter exemplifies PharmaLundensis AB's commitment to sustainability and the prevention of drug-resistant bacterial spread, which is crucial for both environmental health and reducing the risk of global health threats.